CryoCor amends PMA
This article was originally published in The Gray Sheet
Executive Summary
Firm announces Nov. 27 filing of amendment to its CryoCor cardiac cryoablation system PMA after receiving a "non-approvable" letter for the treatment of atrial flutter last February (1"The Gray Sheet" Feb. 27, 2006, p. 15). CryoCor expects FDA review to take six months...
You may also be interested in...
CryoCor’s Cryoablation System For Atrial Flutter Is Non-Approvable, FDA Says
CryoCor is planning to amend its PMA after receiving a non-approvable letter from FDA for its CryoCor cardiac cryoablation system for the treatment of atrial flutter, according to CEO Greg Ayers, MD
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.